Almirall

fiercepharma | May 30, 2019

One by one, drugmakers have been handing over millions of dollars to the U.S. government to settle kickback allegations. And Almirall is the latest.The Spain-based drugmaker agreed to pay $3.5 million to the Department of Justice (DOJ) and $3.1 million to the California Department of Insurance to wrap up claims that it paid doctors to prescribe more of its skin drugs. Based on allegations outlined in a whistleblower lawsuit, the government said that Almirall's Aqua Pharmaceuticals business w...

pharmaphorum | June 25, 2019

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron’s recently approved Dupixent. The companies had struck an option and license agreement in February which granted Almirall European rights to the drug in atopic dermatitis, also known as eczema, and certain other indications. Barcelona-based Almirall paid $30 million up front to Dermira and will pay a further $50 mil...

Pharmaphorum Media Limited | December 05, 2018

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money. Cimzia (certolizumab pegol) was approved in Europe in the new indication of plaque psoriasis earlier this year, adding to a list of uses including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. While there are a number of other anti-TNF drugs approved in psoriasis, in...

Pharmaphorum Media Limited | March 26, 2019

Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for moderate to severe atopic dermatitis – otherwise known as eczema. The Spanish dermatology specialist is conducting a multi-target research collaboration with companies using technology involving DNA-encoded libraries, for targets in atopic dermatitis to develop novel oral chemical entities for patients suffering from moderate to severe atopic dermatitis. DNA-encoded librar...